pico was supposed to be less toxic which would allow for more cycles, which would increase efficacy with reduced side effects
their pfs was actually less then the carboplatin.
without the small cell lung cancer approval they will not be able to partner the drug. any money that they raise will be highly dilutive unless they do something overnight today because dummies bought the stock on the data they released which wasn't very good.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.